A 52 Week, Randomised, Double Blind, Multinational, Multicentre, 4-arm Parallel Group Trial to Assess the Efficacy and Safety of 3 Doses of CHF 6532 Compared to Placebo on Top of Standard of Care in Patients With Uncontrolled Severe Eosinophilic Asthma
Latest Information Update: 07 Sep 2021
At a glance
- Drugs Timapiprant (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms PERSEA
- Sponsors Chiesi Farmaceutici
Most Recent Events
- 30 Aug 2021 Status changed from recruiting to discontinued.
- 03 May 2021 This trial has been completed in Poland (End Date: 01 Feb 2021), according to European Clinical Trials Database record.
- 11 Feb 2021 This trial has been discontinued in Greece, according to European Clinical Trials Database record (2021-02-01)